Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 20Recruiting 12Unknown 5Withdrawn 2Terminated 1Suspended 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 503Breast 39Gastrointestinal 30Gynecologic 26Thoracic 22Dermatologic 13Head & Neck 12Sarcoma 7Lymphoid 7Plasma cell 5Other hematologic neoplasm 5CNS 4Other solid neoplasm 2Other 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 51Thyroid Neoplasms 19Thyroid Cancer, Papillary 16Carcinoma, Neuroendocrine 16Pheochromocytoma 11Adrenocortical Carcinoma 11Thyroid Carcinoma, Anaplastic 10Gastro-enteropancreatic neuroendocrine tumor 10Small Cell Lung Carcinoma 9Pituitary Neoplasms 9Paraganglioma 9Multiple Endocrine Neoplasia Type 1 9Lung Neoplasms 8Adenoma, Islet Cell 8Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Medullary 6Adenocarcinoma, Follicular 6Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Carcinoid Tumor 5Somatostatinoma 4Neuroblastoma 4Neoplasm Metastasis 4Colorectal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Brain Neoplasms 4

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × Endocrine × Clear all
NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡